Hyperuricemia is a significant risk factor for nonalcoholic fatty liver disease (NAFLD). It may also have an impact on the histologic severity of NAFLD. However, data on this association are limited. We conducted this meta-analysis to investigate the relationship of serum uric acid with liver histologic severity as determined by NAFLD activity score (NAS) in patients with NAFLD.
MEDLINE and EMBASE databases were searched through August 2016 for studies that investigated the association between hyperuricemia and NAS among patients with biopsy-proven NAFLD. Pooled odds ratio and 95% confidence interval were calculated using a random-effects model (generic inverse variance method). The between-study heterogeneity of effect size was quantified using the Q statistic and I2.
Five observational studies with 777 NAFLD patients were identified. Patients with NAFLD who had hyperuricemia had a high NAS (defined as score of ≥5) significantly more often than did those without hyperuricemia with a pooled odds ratio of 2.17 (95% confidence interval: 1.51–3.12). The statistical heterogeneity was low, with I2 of 16% (Pheterogeneity=0.31).
In patients with NAFLD, hyperuricemia is associated with a higher degree of histological liver damage. Further studies are required to establish the role of uric acid-lowering therapy among these patients.
aDepartment of Internal Medicine, University of Hawaii, Honolulu, Hawaii
bDepartment of Internal Medicine, Norwalk Hospital, Norwalk, Connecticut
cDepartment of Internal Medicine, Bassett Medical Center and Columbia University College of Physicians and Surgeons, Cooperstown, New York
dDepartment of Internal Medicine, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA
eDepartment of Medicine, King Chulalongkorn Memorial Hospital
fDepartment of Medicine, Division of Rheumatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
Correspondence to Veeravich Jaruvongvanich, MD, Department of Internal Medicine, University of Hawaii, Honolulu, HI 96817, USA Tel: +1 808 542 1939; fax: +1 808 586 7486; e-mail: firstname.lastname@example.org
Received March 15, 2017
Accepted June 1, 2017